Unlocking the Potential of CABP2: A novel Drug Target and Biomarker for Chronic Pain Management

Target Name: CABP2

NCBI ID: G51475

CABP2

Unlocking the Potential of CABP2: A novel Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50 million adults experience chronic pain, representing 12% of the global population. Chronic pain can be caused by various conditions, such as fibromyalgia, rheumatoid arthritis, neuropathy, and cancer, leading to significant morbidity and an increased quality of life (QoL) negatively affected by the persistent discomfort.

The current treatment options for chronic pain are limited and often involve a combination of painkillers, lifestyle modifications, and physical therapy. While these approaches can alleviate pain, they may have potential side effects and may not provide long-term relief. Therefore, there is a need for new, more effective treatments to manage chronic pain.

CABP2: A novel drug target and biomarker

CABP2, also known as CaBP2, is a protein that is expressed in various tissues, including the brain, spleen, and lungs. It is a key regulator of the calcium homeostasis and has been implicated in the development and progression of chronic pain conditions.

Recent studies have demonstrated that CABP2 plays a crucial role in the modulation of pain perception and the development of chronic pain. Researchers have found that mice or human subjects with decreased or absent CABP2 had reduced pain sensitivity compared to their wild-type counterparts. Additionally, overexpression of CABP2 has been shown to exacerbate pain sensitivity in both mouse models and human subjects.

CABP2 has also been shown to be involved in the modulation of pain modalities, including pain processing and neuroinflammation. For instance, CABP2 has been shown to reduce the intensity of pain-related thermal hyperthermia in mouse models of pain. Furthermore, CABP2 has been shown to reduce neuroinflammation in various experimental models of chronic pain.

Despite the promising findings, the exact mechanism of CABP2's involvement in chronic pain remains unclear. Therefore, targeting CABP2 as a drug target or biomarker could provide new insights into the treatment of chronic pain and may lead to the development of new, more effective therapies.

CABP2 as a drug target

Given the potential involvement of CABP2 in the modulation of chronic pain, researchers have began exploring its potential as a drug target. Several small molecules have already been shown to interact with CABP2 and to modulate pain sensitivity in various experimental models of chronic pain.

One of the most promising compounds is N-Acetyl-L-Tyrosine (NALT), a neurotransmitter that has been shown to modulate pain processing in CABP2-deficient mice. NALT has been shown to increase pain sensitivity in these mice, but it also decreased the activity of a neurotransmitter called GABA, which is involved in the modulation of pain processing.

Another compound that has shown promise is Blockade, a small molecule that has been shown to inhibit the activity of a protein called TrkB, which is involved in the modulation of pain processing. Blockade has been shown to decrease pain sensitivity in CABP2-deficient mice and to modulate pain processing in various experimental models of chronic pain.

CABP2 as a biomarker

In addition to its potential as a drug target, CABP2 has also been shown to be a potential biomarker for chronic pain. The decreased pain sensitivity observed in CABP2-deficient mice can be used as a measure of pain intensity, and the modulation of pain processing by CABP2-interactive compounds can be used as a measure of its involvement in pain modulation.

CABP2 has also been shown to be involved in the modulation of pain-related thermal

Protein Name: Calcium Binding Protein 2

Functions: Required for sound encoding at inner hair cells (IHCs) synapses, likely via inhibition of the inactivation of voltage-gated calcium channel of type 1.3 (Cav1.3) in the IHCs (PubMed:28183797). Required for the normal transfer of light signals through the retina (By similarity)

The "CABP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CABP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets